{"id":"W2897890026","doi":"10.1016/s0140-6736(18)31946-9","title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":359,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Janssen Biotech; Pfizer Pharmaceuticals; Chugai Pharmaceutical; Genentech; Eisai; Astellas Pharma; UCB; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Gilead Sciences; AbbVie; Sanofi; Novartis; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ixekizumab; Medicine; Adalimumab; Placebo; Ankylosing spondylitis; Internal medicine; Axial spondyloarthritis; Spondylitis; Secukinumab; Physical therapy; Sacroiliitis; Disease; Psoriatic arthritis; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009568717,0.0005114886,0.00294248,0.0003587278,0.0002300219,0.00006048802,0.0002426921,0.0001158847,0.00003925441],"category_scores_gemma":[0.0002599432,0.000233684,0.0002973417,0.000638832,0.0007962806,0.0001462954,0.00003925466,0.0001890978,0.000001816652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001478435,"about_ca_system_score_gemma":0.0001330552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008800853,"about_ca_topic_score_gemma":0.001843119,"domain_scores_codex":[0.9961902,0.0009175253,0.001242258,0.000589085,0.0004320462,0.0006288874],"domain_scores_gemma":[0.9973556,0.0009840255,0.0006456628,0.0007019102,0.0001598848,0.0001529326],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9552563,0.007249104,0.01642955,0.00006234404,0.0008141455,0.0001996736,0.007684531,0.000002103113,0.00003555644,0.00001084442,0.00001648146,0.01223936],"study_design_scores_gemma":[0.9389255,0.03570307,0.0217778,0.0009125713,0.0007322038,0.00003864881,0.00131532,0.0001173055,0.0001396064,0.00003490976,0.00008267649,0.000220363],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840329,0.0009858593,0.00000284012,0.0003178604,0.0001380682,0.01360607,0.0007131162,0.00003250259,0.0001708257],"genre_scores_gemma":[0.9956723,0.002181539,0.00005453928,0.00005143035,0.000329275,0.001262912,0.0003990371,0.00003205785,0.00001686794],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02845397,"threshold_uncertainty_score":0.9529358,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04721040121979949,"score_gpt":0.3179318293990595,"score_spread":0.27072142817926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}